Abstract
Posterior reversible encephalopathy syndrome (PRES) is a serious neurologic disorder marked by acute neurologic symptoms and classic neuroimaging lesions. It occurs in the setting of certain medications and predisposing clinical conditions. We present a case of PRES in a patient with mantle cell lymphoma treated with systemic and intrathecal chemotherapy. The literature suggests a propensity for PRES to arise from the combination of malignancy, intensive induction chemotherapy, and intrathecal administration. PRES is an uncommon and underappreciated complication of certain chemotherapy regimens. The risk of PRES in this setting needs to be considered in managing patients with hematologic malignancies.
Original language | English (US) |
---|---|
Pages (from-to) | e137-e142 |
Journal | American Journal of Therapeutics |
Volume | 21 |
Issue number | 5 |
DOIs | |
State | Published - Jan 1 2014 |
Externally published | Yes |
Keywords
- Chemotherapy
- Cytarabine
- Intrathecal chemotherapy
- Lymphoma
- Methotrexate
- PRES
- PRLS
- Posterior reversible encephalopathy
- Posterior reversible leukoencephalopathy
ASJC Scopus subject areas
- Pharmacology
- Pharmacology (medical)